Prof Moganavelli (Mogie) Singh obtained a PhD (Biochemistry) from the University of KwaZulu-Natal in 2006. She is currently a Professor, Researcher and Head of the Nano-Gene and Drug Delivery Laboratory at the University of KwaZulu-Natal, Durban, South Africa. Her interdisciplinary research includes the development and biological evaluation of organic and inorganic nanoparticles as potential gene and drug delivery vehicles for cancer and in immunotherapy. Prof Singh has >100 publications to her credit, and is a current member of the ESGCT and ASGCT.
The Nano-Gene and Drug Delivery group actively pursue research in Nanomedicine, focusing on design and formulation of nanoparticle and polymeric assemblies for drug delivery, and non-viral therapeutic gene delivery. We study the essential pharmaceutical concepts involved in drug solubilization, controlled drug release, and drug targeting. In addition, the conjugation, protection, stabilization and safe delivery of therapeutic DNA, mRNA, siRNA and miRNA molecules are currently under investigation. This will enable us to explore therapeutic strategies that involve novel nanomedicines that are bio-responsive, synergistic and theranostic, aiming for progress against selected cancers, and neurodegenerative disorders. This is in addition to collaboration with NWU on the determination of anticancer activities of drugs and novel chemical compounds/plant extracts.